




# ACAN







## ACE2




# AGT




AGTR1




## AGTR2



COL1




## COL2







CTSD




# IL-1b




# IL6




## IL6/IL10 ratio




# IL8




# IL8/IL10 ratio






# MAS1







MMP1



## MMP3





**Supplementary Figure S3.** Gene expression analysis in human NP cells for Candesartan (1 $\mu$ M, 10 $\mu$ M, 100 $\mu$ M), the MAS-receptor agonist AVE 0991 (1 $\mu$ M, 10 $\mu$ M, 100 $\mu$ M), and the AGTR2-receptor agonist CGP-42112A (0.1 $\mu$ M, 1 $\mu$ M, 10 $\mu$ M) with 4 h of exposure in in-inflammatory settings (TNF- $\alpha$  addition). DMSO (0.1 $\mu$ L/ml, 1 $\mu$ L/ml, 10 $\mu$ L/ml; shown in  $\mu$ L volume on the x-axis) was used as the solvent control. Fold change values normalized to the baseline (day 0) are shown. n=4 biological replicates and n=3 technical replicates per donor were assessed. Mean and standard error of the mean (SEM) are shown. #: compared to Control; %: compared to TNF- $\alpha$ ; &: compared to TNF- $\alpha$ +CGP42122A 0.1  $\mu$ M; §: compared to TNF- $\alpha$ +CGP42122A 1  $\mu$ M; †: compared to TNF- $\alpha$ +CGP42122A 10  $\mu$ M; ?: compared to TNF- $\alpha$ +Candesartan 1  $\mu$ M; +: com-pared to TNF-alpha+Candesartan 10  $\mu$ M; ^: compared to TNF- $\alpha$ +Candesartan 100  $\mu$ M; \$: com-pared to TNF-alpha+AVE0991 10  $\mu$ M; !: compared to TNF-alpha+AVE0991 100  $\mu$ M. \* p < 0.05; \*\* p < 0.01; \*\*\* p < 0.001; \*\*\*\* p < 0.0001.